Shanghai Fosun Pharma (Group) Co., Ltd is a pharmaceutical and healthcare group founded in 1994. The company operates in pharmaceutical manufacturing, medical devices, medical diagnostics, and healthcare services. It also covers pharmaceutical distribution and retail through its associate Sinopharm Group. Key subsidiaries include Shanghai Henlius, which develops biopharmaceuticals, and Fosun Adgenvax, a vaccine platform enterprise. The company’s product portfolio includes the Artesun antimalarial drug, the Hanlikang biosimilar, the Yikaida CAR-T cell therapy product, and the Suxin small-molecule drug. It also distributes the Comirnaty mRNA vaccine in specific markets. The company serves markets in China, the United States, Europe, Africa, India, and Southeast Asia. Its research focuses on oncology, immunology and inflammation, neurodegenerative diseases, chronic diseases, and rare diseases, utilizing antibody, ADC, small molecule, and cell therapy platforms.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage fosunpharma.com
Sector Healthcare IR page fosunpharma.com/investor
Tags
innovative drugs, biopharmaceuticals, medical devices, medical diagnostics, healthcare services, vaccines, cell therapy, oncology, immunology, neurodegenerative diseases, rare diseases, antibody drugs, Shanghai Henlius, Fosun Adgenvax, Sinopharm Group, Artesun, Hanlikang, Yikaida, Suxin, Comirnaty, Zercepac, Hanshuang
Press page —

Metrics

Valuation  
Market cap HK$ 39.986B
Market cap (USD) $ 5.096B
P/E 10.54
PEG —
P/BV 0.54
P/S 0.80
P/OCF 6.17
P/FCF —
Dividend yield 3.0%
Turnover / mcap 0.13%
Returns  
ROE 5.5%
ROI 4.1%
ROIC 4.1%
Profit margin 8.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -3.4%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 35.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Revenue 41.498B 40.91B 41.249B 43.811B 38.858B 30.163B 28.389B 24.714B 18.362B 14.506B 12.502B 11.938B 9.921B 7.278B 6.433B
Net profit 3.371B 2.77B 2.399B 3.737B 4.735B 3.663B 3.322B 2.708B 3.125B 2.806B 2.46B 2.113B 2.027B 1.564B 1.166B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Share price 18.73 — 17.04 19.8 46.3 51.13 21.31 18.84 32.75 — — — — — —
Price performance 12m — — -0.19 -0.59 -0.03 1.41 0.09 -0.43 — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Shanghai Fosun Pharma (Group) Co., Ltd (ticker 2196), listed in Hong Kong.

ETFs Holding Shanghai Fosun Pharma (Group) Co., Ltd

ETF Weight in ETF Shares Market value As of
DFEV 0.02% 163,000 $ 344.3K Nov 12, 2026
DFEM 0.01% 483,500 $ 1.021M Nov 12, 2026
DFSE 0.01% 24,000 $ 50.694K Nov 12, 2026
DFAE 0.00% 203,000 $ 428.79K Nov 12, 2026
DFAX 0.00% 223,500 $ 472.092K Nov 12, 2026
AVEM 0.00% 92,500 $ 189.743K Nov 16, 2026
AVSE 0.00% 500 $ 1,025.64 Nov 16, 2026